Carlsmed raised $30 million in series B funding to ramp up commercialization of its personalized spine implants, the devicemaker said April 19.
Funding was led by B Capital group, and existing investors participated in the round, according to a news release. Widya Mulyasasmita, PhD, a senior investor at B Capital Group, will join Carlsmed's board as an observer.
Carlsmed's Aprevo implants are patient-specific and designed for spinal fusions. The device was granted two CMS payments in 2021.